secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001558370-25-002396
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports FY2024 net loss of $55.7M; cash $68.6M, LNCB74 Phase 1 advancing
--------------------------------------------------------------------------------

- Net loss of $55.7M in FY2024 improved from $62.7M in FY2023; R&D expenses $41.5M, G&A $15.7M, both down YoY.
- Cash, equivalents, and marketable securities $68.6M at Dec 31, 2024 (vs $108.3M); expected to fund operations into H2 2026.
- LNCB74 (B7-H4 ADC) Phase 1: completed cohort 1 in Feb 2025, currently dosing cohort 2; backfill cohorts planned H2 2025.
- Preclinical non-oncology programs (NC181 for Alzheimer's, NC605 for osteogenesis imperfecta) seeking partnerships.
- Potential IND filings for NC181 and NC605 within 12-18 months if partner or third-party funding secured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025002396/0001558370-25-002396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025002396/nxtc-20250306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer